<DOC>
	<DOCNO>NCT01480674</DOCNO>
	<brief_summary>This observational study characterize retrospectively patient HER2-positive metastatic locally advanced breast cancer receive treatment Herceptin ( trastuzumab ) 1st line without progression least three year . Patients follow prospectively one year .</brief_summary>
	<brief_title>An Observational Study Patients With HER2-Positive Metastatic Locally Advanced Breast Cancer Treated With Herceptin ( Trastuzumab ) 1st Line Without Progression For 3 Years</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Female patient , &gt; /= 18 year age HER2positive metastatic breast cancer locally advance breast cancer Systemic treatment include Herceptin 1st line therapy Without progression least 3 year begin Herceptin treatment Alive alive treat treated Herceptin time inclusion Disease progression &lt; 3 year begin 1stline therapy Herceptin</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>